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There are various region-specific challenges to the diagnosis and effective treatment of venous thromboembolism in
Latin America. Clear guidance for physicians and patient education could improve adherence to existing guidelines.
This review examines available information on the burden of pulmonary embolism and deep vein thrombosis in Latin
America and the regional issues surrounding the diagnosis and treatment of pulmonary embolism and deep vein
thrombosis. Potential barriers to appropriate care, as well as treatment options and limitations on their use, are
discussed. Finally, an algorithmic approach to the diagnosis and treatment of venous thromboembolism in ambulatory
patients is proposed and care pathways for patients with pulmonary embolism and deep vein thrombosis are outlined
for primary care providers in Latin America.
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’ INTRODUCTION
Although multiple studies have evaluated the epidemiology
of venous thromboembolism (VTE) in European and American
populations, there is limited evidence on the prevalence of VTE
and the burden of disease in Latin America. Evidence from
a study in the United States suggests that there are differences
in the incidence of VTE among white, black, Hispanic, and
Asian populations (1). Thus, it may not be appropriate to
simply extrapolate the prevalence of VTE in Latin America
from data obtained from European and U.S. populations. In the
ENDORSE II study (2), approximately 50% of hospitalized
patients from across 43 hospitals in Mexico were identified as
being at risk of deep vein thrombosis (DVT) or pulmonary
embolism (PE) and in a Brazilian study across 3 hospitals, a
similar proportion of hospitalized patients were considered to
be at high risk of DVT or PE (3). Data from an Argentinian
study (4) estimated an incidence rate of 0.7 per 1,000 person-
years for total VTE (0.48 and 0.22 for DVTand PE, respectively)
based on the incidence rate observed at a Buenos Aires hospital
and extrapolated to the entire Argentinian population. The in-
hospital mortality rate from VTE was estimated at 19% in an
Argentinian hospital by Mazzei et al. (5) and 14.1% in a
Brazilian hospital by Volschan et al. (6). A large autopsy-based
analysis in a Brazilian hospital identified PE as the cause of
death in 2.5% of all deaths of hospitalized patients (7). Thus,
available data indicate a significant disease burden in Latin
America in terms of morbidity and mortality as well as cost to
the healthcare system.
There are various regional challenges to effective VTE
diagnosis and treatment in Latin America. A cross-sectional
study of internal medicine practitioners in Mexico revealed that
the awareness of risk factors for VTE and recommended
methods of diagnosis was low (8). A significant proportion of
patients diagnosed with VTE in Latin American countries may
not receive appropriate anticoagulation and some patients at
risk of VTE do not receive appropriate prophylaxis (5,9-16).
A Venezuelan study of characteristics of patients with VTE
observed that patients with VTE often present with comorbid-
ities that may complicate treatment decisions (17), and
subsequent studies implicated these comorbidities as poten-
tially affecting the decision to anticoagulate (18). In a study in
Brazil, only 26% of patients at moderate or high risk of VTE
received prophylactic anticoagulation (3). In a study of the
adequacy of prophylactic anticoagulation in 28 institutions
across Argentina (19), surgical patients were more likely to
receive adequate prophylaxis than medical patients (71% vs.
63%). By contrast, the Epidemiologic International Day for the
Evaluation of Patients at Risk for Venous Thromboembolism in
the Acute Hospital Care Setting (ENDORSE) study (20)
observed that medical patients were more likely than surgical
patients to receive adequate prophylactic anticoagulation in
Mexico, Venezuela, Colombia and Brazil. This finding high-
lights potential differences in educational needs across Latin
American regions.
The International Society on Thrombosis and Haemostasis
recently performed a worldwide survey as part of the firstDOI: 10.6061/clinics/2016(01)07
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World Thrombosis Day. Of the Argentinians surveyed, the
majority did not recognize the symptoms of DVTor PE (21,22).
Globally, concern about thrombosis was second highest in
Argentina, but fewer than half of Argentinians surveyed
recognized that thrombosis is a preventable disease (21).
Clear guidance and education on how comorbidities may
affect therapy might increase healthcare providers’ adherence
to existing guidelines (23-25). Pilot studies using programs
and guidance protocols to facilitate treatment decisions in
Brazil and Argentina have demonstrated improvements in
the level of appropriate anticoagulation administered to
patients with or at risk of VTE (26,27). The aim of this review
is to outline an algorithmic approach for primary care pro-
viders in Latin America for VTE diagnosis in ambulatory
patients and to discuss current and emerging options for the
treatment of these patients.
Venous Thromboembolism: Deep Vein Thrombosis
and Pulmonary Embolism
VTE, which includes DVT and PE, is associated with
significant morbidity and is a leading cause of cardiovascular
death worldwide (28). DVT is a common complication of and
the most common cause of rehospitalization following any
major surgery. Although less common than DVT, PE is a
serious complication that can occur after surgery or in
association with cancer, other chronic illnesses and preg-
nancy (28). Various risk scores have been developed to
estimate VTE risk in specific patient populations, such as the
Khorana score in patients with cancer (29) and the Caprini
score in surgical patients (30).
The Khorana score (29) was developed for use in patients
with cancer initiating a new chemotherapy regimen as a
simple predictive risk model to identify patients at highest
risk for VTE who would most benefit from thromboprophy-
laxis. The scoring system assigns 2 points for the stomach or
pancreas as the primary site of cancer or 1 point each for a
primary site in the lungs or genitourinary tract, excluding
prostate, lymphoma, or gynecological cancer. An additional
point is assigned for each of the following risk factors:
pre-chemotherapy platelet count of 350  108/L or more;
hemoglobin level below 10 g/dL or use of erythrocyte
growth factors; a pre-chemotherapy leucocyte count greater
than 11  109/L; or a BMI of 35 or higher. Patients are
categorized as low, medium, or high risk based on their total
scores (0, 1-2, and X3, respectively).
The Caprini score provides a simple checklist for known
VTE risk factors in surgical patients based on a health history
scored by the physician. The most recent version (30)
incorporates approximately 40 different risk factors with
weights of 1 to 5 points each; the total score is used to classify
patients as low (scores of 0-1), moderate (scores of 1-2), high
(scores of 3-4) and highest (scores of 5 or more) risk, each
with a recommended prophylactic regimen.
The Caprini and Khorana scores are recommended by the
American College of Chest Physicians guidelines as an
objective screening method to identify patients at high risk of
VTE who might benefit most from prophylactic anticoagula-
tion (31). However, other specialized VTE risk scores require
more extensive clinical validation.
Deep vein thrombosis
DVT can occur in either the upper or lower extremities. In
a recent international study by Lamontagne et al. of 3,746
medical/surgical patients in intensive care, 98% of DVT in
this population involved thromboses of the lower extremities
(32). Of the remaining events, 72% were upper extremity
DVT (UEDVT) (32). Patients who experience VTE are at
increased risk of recurrence (33,34), and VTE is often
associated with long-term, clinically significant complica-
tions, including post-thrombotic syndrome and chronic
thromboembolic pulmonary hypertension.
DVT of the lower extremities can be classified as proximal
or distal (occurring above or below the popliteal vein,
respectively). The former is a more serious condition due to
the higher associated risk of thromboembolism. DVT can
present as pain or tenderness of the leg, with swelling,
erythema, discoloration, or surface vein distension, but also
frequently occurs as an asymptomatic condition. The presence
of symptoms is often insufficient for diagnosis because other
conditions can cause similar symptoms. However, when
associated with known risk factors, these symptoms can
provoke clinical suspicion of DVT warranting further evalua-
tion (35).
UEDVT accounts for 10% or less of all DVT cases and may
be associated with local compressive factors or central
venous catheter use (36). Clinical outcomes for UEDVT are
similar to those for DVT of the lower extremities (37,38),
although the recurrence rate is much lower. There are no
published randomized, controlled studies of anticoagulation
in UEDVT, but observational studies suggest that treatment
with anticoagulants is effective (39,40). In the absence of
further information, treatment for UEDVT should be the
same as for DVT of the lower extremities (31,41).
Pulmonary embolism
PE is difficult to diagnose based on clinical symptoms
alone and may have a broad spectrum of presentations
ranging from shortness of breath, tachypnea and syncope to
fever, side stitch and hemoptysis.
Shock and hypotension indicate high-risk PE. Although
massive PE is characterized by hypotension (systolic blood
pressure o90 mm Hg), it can also be associated with
syncope and bradycardia and can cause cardiac arrest with
sudden death. Although massive PE is associated with a
90-day mortality risk of 52-58%, it accounts for only approx-
imately 5% of all PE events (42,43).
Submassive PE is characterized by the absence of
hypotension and the presence of right ventricular dysfunc-
tion or myocardial necrosis due to ischemia of the right heart.
Tachycardia may suggest right ventricular dysfunction, but
has limited specificity. Additional laboratory parameters
indicative of myocardial ischemia or an echocardiogram/
computed tomography scan revealing an enlarged right
ventricle are also required to confirm a diagnosis of sub-
massive PE (43,44). This condition is associated with a parti-
cularly high event mortality of approximately 30% and early
identification of patients and hospitalization for treatment
are imperative. In low-risk or nonmassive PE, systolic blood
pressure remains normal and the markers that define
massive or submassive PE are absent (42,43). These low-risk
patients may be appropriate for ambulatory management if
conditions allow.
Overall, PE is associated with a 90-day mortality of
approximately 10–15% (44,45). Suspected PE should be
considered a matter of clinical urgency due to the high
mortality and morbidity associated with this condition. In an
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epidemiological model of fatal PE, 34% of affected patients
experienced sudden death, 59% were undiagnosed during
life and treated as having cardiac insufficiency or pneumonia
and only 7% were correctly diagnosed with PE before death
(47). Therefore, a large number of patients with PE may be
misdiagnosed and would benefit significantly from a reliable
diagnostic algorithm, particularly in countries where aware-
ness of the disease is low.
Diagnosing VTE in primary care
Data from the International Society on Thrombosis and
Haemostasis ‘‘World Thrombosis Day’’ survey for Argentina,
the only Latin American country included in the survey,
indicate that the majority of the Argentinian population has
little awareness or knowledge of DVT, PE, or their con-
sequences, consistent with the results for all other countries
evaluated in the survey (21,22). Consequently, the ability of
general practitioners to diagnose this condition is critical.
In managing patients presenting with symptoms of DVT,
such as a unilateral pitting edema or swollen and painful leg, or
where there is clinical suspicion of DVT, the Wells DVT score or
simplified Wells for predicting probability of DVT should be
calculated before imaging is performed (48). If the score
indicates a high probability of DVT, in the absence of contra-
indications, anticoagulation with heparin or similar agents
should be initiated immediately while confirmatory tests are
performed. However, if the score indicates a low probability of
DVT, a negative D-dimer test can rule out a diagnosis of DVT
without requiring imaging, although the D-dimer cut-off value
used should be age-adjusted for older patients (age  10 mg/L
for patients 450 years of age). When screening a low-risk
patient, treatment may be delayed only if the tests will be
available within a reasonable time frame (31). A diagnostic
algorithm for patients with DVT is presented in Figure 1 (35).
In patients presenting with symptoms of PE, such as
hemoptysis, chest pain and shortness of breath, or where there
is clinical suspicion of PE, the Wells PE score (49) or revised
Geneva score (50) should be calculated and used to predict
the probability of PE before imaging is performed. As in DVT,
for patients for whom there is a strong clinical suspicion of
PE but no firm diagnosis, unless there are contraindications to
heparin use, anticoagulation with unfractionated heparin,
low-molecular-weight heparin (LMWH), or fondaparinux
should be maintained until the diagnosis is confirmed (31).
Bivalirudin or fondaparinux may be considered for patients
who cannot receive heparin derivatives (e.g., as a result of
heparin-induced thrombocytopenia) (31). The Pulmonary
Embolism Severity Index and Simplified Pulmonary Embo-
lism Severity Index (Table 1) can be used to assess the severity
of the event based on 30-day survival probability (51,52).
A diagnostic algorithm based on the European Society of
Cardiology guidelines for patients with suspected PE (52) in
the absence of hypotension and shock (i.e., normotensive) is
shown in Figure 2. For patients with suspected PE with
suspected shock or hypertension, the European Society of
Cardiology guidelines recommend that an angiography/
helical CT should be performed if available, and treatment
for PE initiated for positive findings (52). If the CT findings
are negative, alternative causes for hemodynamic instability
should be explored (52). If CT angiography is not immedi-
ately available, echocardiography should be performed to
check for right ventricle (RV) overload and, if confirmed, the
patient should be stabilized and then sent for CT (52). If the
patient has confirmed RV overload, but cannot be stabilized
or CT is not immediately available, treatment should be
initiated for PE (52). In the absence of RV overload, alternative
causes of hemodynamic stability should be investigated (52).
Treatment options: guidelines, anticoagulant
choices and treatment duration
The guidelines for individual countries in Latin America are
generally consistent with those of the American College of
Chest Physicians (23-25,31,53). Guidelines on antithrombotic
therapy for VTE recommend an anticoagulant for the treatment
of acute VTE (31) to prevent further growth of the throm-
bus rather than to deplete the existing thrombus, for which
fibrinolysis may be required. After the acute phase of treatment,
the treatment pathways for DVT and PE are similar (31,54),
reflecting that these are both manifestations of the same disease.
The recommended duration of anticoagulation varies, depend-
ing on the cause of the initial event. Anticoagulation for
3 months is appropriate when there is a transient and reversible
cause, such as surgery, trauma, or hospitalization; 6 months or
more is appropriate for patients experiencing a first event of
idiopathic VTE; and 12 months or more (possibly indefinitely,
subject to regular review) is appropriate for patients with active
neoplasia, recurrent idiopathic VTE, high-risk thrombophilia,
or antiphospholipid antibodies (25). However, anticoagula-
tion may be discontinued after the initial 3 months of
treatment if the risk of bleeding is high (25). Due to the lower
risk of recurrence associated with UEDVT, in the absence of
additional factors, 3 months of anticoagulation treatment may
be sufficient, even in cases of spontaneous DVT.
Initiation of parenteral anticoagulation is recommended
without delay in patients with a high or intermediate
probability of PE while diagnostic work-up is in progress.
Heparin, LMWH, and fondaparinux are the recommended
forms of parenteral anticoagulation in the acute phase
(25,31,53). In parallel with parenteral anticoagulation, treat-
ment with a vitamin K antagonist (VKA) is recommended,
with a target international normalized ratio (INR) of 2.0-3.0.
For inpatients with PE who have a high risk of bleeding or
who are hemodynamically unstable and for whom precise
anticoagulation control and the ability to quickly reverse
anticoagulation may be desirable, unfractionated heparin
may be preferred to LMWH due to its short half-life and the
availability of an antidote, protamine (31).
Outpatient treatment is often appropriate for patients with
low risk of acute DVT (54). A recent publication describes a
very low rate of complications in Argentina in this setting,
with only one major bleed and no recurrences in 359 ambu-
latory patients with DVT (55). VKAs can be effective for
anticoagulation but have a slow onset/offset of action and
require regular monitoring, which may be a barrier to their
use, particularly in rural areas where access to anticoagulation
specialists may be limited. When VKAs are used without
careful monitoring and adjustment, there is an increased risk
that patients will be outside the target therapeutic range (TTR)
for longer periods, which is associated with an increased risk
of both DVT recurrence and bleeding (56). Data from Latin
America have included TTR values as low as 44% for atrial
fibrillation patients in some locations (57). Results from
international phase III studies in patients with atrial fibrilla-
tion, such as the Randomized Evaluation of Long Term
Anticoagulant Therapy (RE-LY) trial, identified some Latin
American countries in which the mean TTR was as low as
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49% compared with the study average of 64% (58). A low TTR
in this region has also been recorded in clinical trials, which
have the advantages of patient selection according to trial
criteria and close support and monitoring. Real-world TTR
levels are likely to be at least 10-20% lower (59). This low rate
of ‘‘in range’’ therapeutic anticoagulation could be a major
disadvantage in Latin America and may be one of the region’s
most important challenges with respect to oral anticoagulation
with VKAs. However, a recent study exploring TTR across
14 anticoagulation clinics in Argentina that included 1,190
consecutive patients with atrial fibrillation observed a mean
TTR of 66.6%, a value similar to that observed in international
therapeutic clinical trials and in Nordic countries, where care
is largely available from highly developed socialized health
systems, indicating that high-quality anticoagulation with
VKAs is possible in Latin America (60).
Direct oral anticoagulants
When the American College of Chest Physicians 2012
guidelines for the treatment of VTE were issued, there was
insufficient clinical experience with direct oral anticoagulants
(DOACs) to support recommendations for these agents over
VKAs or LMWH (31). However, publications and clinical data
Figure 1 - Diagnosis and treatment pathway for a patient presenting with symptomatic DVT. DOAC, direct oral anticoagulant (e.g.,
rivaroxaban, apixaban, dabigatran, or edoxaban); DVT, deep vein thrombosis; PE, pulmonary embolism. *Note: D-dimer cut-off should
be age adjusted (age  10 mg/L) in patients 450 years of age. Figure adapted from information in (35), (53), and (92).
39
CLINICS 2016;71(1):36-46 Latin America VTE
Ceresetto JM.
from real-world use of DOACs have since become available and
recommendations for their use were included in the more recent
European Society of Cardiology guidelines (53). These new
drugs are approved or under consideration for this indication by
various regulatory agencies. DOACs offer rapid onset of action
and predictable pharmacokinetics, obviating the need for regular
monitoring in routine clinical use and enabling convenient oral
administration. These qualities are significant advantages for
DOACs comparedwith VKAs, and thus DOACs are particularly
useful for outpatient treatment.
Ambulatory patients and those without cancer requiring
long-term treatment for VTE may be good candidates for new
oral anticoagulants if they have a low risk of bleeding and
adequate renal and hepatic function. Several international
experts have proposed that DOACs should be considered for
patients in whom adequate anticoagulation with VKAs cannot
be maintained in the therapeutic range despite good adherence
to treatment and regular monitoring (61). Conversely, patients
with poor adherence to treatment, patients with an underlying
disease that requires hospitalization, or patients requiring triple
antithrombotic therapy (e.g., dual antiplatelet therapy plus
anticoagulant) may not be candidates for DVT treatment with
DOACs. In addition, due to the relative scarcity of clinical
experience, patients with cancer and thrombosis, antiphos-
pholipid syndrome, high-risk thrombophilia, or thrombosis at
an unusual site (e.g., splanchnic or cerebral vein thrombosis)
should not be considered for DOACs until clinical trials have
demonstrated the utility of these agents for these indications.
In patients with severe renal impairment (creatinine clearance
o30 mL/min), hepatic impairment (Child-Pugh category B or
C), pulmonary thromboembolism with high burden of disease
or a high-risk simplified Pulmonary Embolism Severity Index
score (Table 1), severe hypotension, dilated right ventricle, or
phlegmasia alba dolens (milk leg) (for the potential use of
fibrinolytics), patients who are pregnant or breastfeeding and
pediatric patients, traditional anticoagulant treatment either
with heparins alone or in combination with VKAs may be a
superior option (62,63).
The results of key studies of each of the DOACs are
summarized in Table 2 (64-71). In light of these clinical trial
results, it will be important to reconsider treatment guidelines in
some patients as new agents become available. Xareltos
(rivaroxaban) is already approved for the treatment of VTE/
PE in Argentina, Brazil, Chile, Colombia, Mexico and Peru.
Pradaxas (dabigatran) is approved in Argentina, Brazil, Chile,
Colombia and Mexico, and Eliquiss (apixaban) is currently
approved in Argentina, Chile, Colombia, Mexico and Peru for
this indication. Approval for all 3 agents in additional countries
is expected in the near future. Guidelines for the use of
rivaroxaban, apixaban, or dabigatran in the treatment of DVT
or PE in ambulatory patients are presented in Table 3. At the
time of writing, Savaysat (edoxaban) has not been approved for
this indication in any Latin American country or in Europe and
has yet to be included in the guidelines. However, prescribing
information from the United States, where edoxaban was
recently approved for the treatment of DVT and PE, states that
edoxaban (60 mg once daily for patients with creatinine
clearance 450 to p95 mL/min, reduced to 30 mg once daily
in patients with creatinine clearance 15–50 mL/min, who weigh
p60 kg, or who are taking specific concomitant P-glycoprotein
inhibitor medications) can be used following 5 to 10 days of
initial therapy with a parenteral anticoagulant (72).
Barriers to widespread direct oral anticoagulant use
Access to the healthcare system can present a significant
barrier to care in general, with WHO estimates indicating that
more than 40% of the population of some countries does not
have effective access to healthcare for reasons ranging from
language barriers and a lack of education to a lack of health
infrastructure and lack of access to other public services,
including electricity and sanitation, which thus impairs
adequate provision of healthcare (73). Where access to the
healthcare system is available, one of the major barriers to
appropriate anticoagulation in Latin America is economic; the
high pharmacy cost of outpatient anticoagulation treatment
can make it inaccessible to patients who must pay drug costs
out of pocket (73) and when funded publicly, the use of more
expensive drugs may be restricted or controlled centrally (13).
Consequently, ambulatory patients who would be suitable for
outpatient treatment with new oral anticoagulants may be
admitted to the hospital to receive the first few days of
Table 1 - PESI and sPESI: prognostic scores for severity in patients with acute symptomatic pulmonary embolism.
PESI Score Simplified PESI Score
Variable Points Variable Points
Age 1/year Age 480 years 1
Male sex 10 Cancer 1
Cancer 30 Chronic cardiopulmonary disease 1
Heart failure 10 Heart rate X110 beats/min 1
Chronic lung disease 10 Systolic blood pressure o100 mm Hg 1
Heart rate X110 beats/min 20 O2 saturation o90% 1
Systolic blood pressure o100 mm Hg 30
Respiratory rate X30 breaths/min 20
Temperature o36oC 20
Altered mental status 60
O2 saturation o90% 20
Interpretation:
Class I (very low risk): o65 points
Class II (low risk): 66-85 points
Class III (intermediate risk): 86-105 points
Class IV (high risk): 106-125 points
Class V (very high risk): 4125 points
Interpretation:
Low risk: 0 points
High risk: X1 point(s)
PESI: Pulmonary Embolism Severity Index; sPESI: simplified PESI.
Table adapted from (49) and (55).
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treatment as inpatients. In some institutions, patients may be
admitted to receive unfractionated heparin via continuous infu-
sion pump to avoid the high cost of LMWH (13,26), despite
the greater overall cost to the healthcare system of doing so
(74,75). Thus, while it may be theoretically possible for 80% of
patients with DVT to be managed on an outpatient basis
(76,77), the actual rate of outpatient care is much lower and
both institutional and healthcare system costs are increased.
Across many parts of Latin America there is a lack of knowl-
edge regarding the pathology of VTE, leading to late consulta-
tion. Furthermore, even if a clinician has adequate evidence to
suspect a diagnosis requiring anticoagulation, therapy is occa-
sionally not started until the diagnosis has been confirmed, which
in some institutions results in an additional delay of several days
while waiting for confirmation by ultrasound.
In some regions of Latin America, particularly rural areas,
access to an anticoagulation clinic may be difficult. Therefore,
in many countries, patients may be managed by general
physicians (rather than anticoagulation specialists), who may
lack detailed knowledge of how to evaluate anticoagulated
patients. Non-specialists are also less likely to be aware of the
range of available treatments and when oral anticoagulation
is prescribed, may choose traditional anticoagulation, such as
a VKA, based on familiarity, despite the additional burden of
monitoring.
Emergency reversal of anticoagulant effects
Evidence suggests that 4-factor prothrombin complex con-
centrates may be as useful for managing bleeding related to
Figure 2 - Diagnosis and treatment pathway for a patient presenting with symptomatic PE who is normotensive. CT, computed tomography;
DOAC, direct oral anticoagulant (e.g., rivaroxaban, apixaban, dabigatran or edoxaban); DVT, deep vein thrombosis; PE, pulmonary embolism;
PESI, Pulmonary Embolism Severity Index; sPESI, simplified PESI; VKA, vitamin K antagonist. *D-dimer cut-off should be age adjusted (age 
10 mg/L) in patients450 years of age. wFor patients with renal failure, allergy to contrast dye, pregnant patients, or other contraindications to
CT, a positive lower limb compression ultrasonography finding is sufficient to warrant anticoagulation. Figure 2 adapted from information in
(53), (49), and (93).
41
CLINICS 2016;71(1):36-46 Latin America VTE
Ceresetto JM.
factor Xa (FXa) inhibitors and direct thrombin inhibitors as they
are for bleeding related to VKAs (78-81); however, the use of
DOACs has been limited by the lack of a specific active reversal
agent or antidote for use in bleeding management or prior to an
emergency procedure. Idarucizumab (Praxbind), an antibody
fragment–based reversal agent for dabigatran, was approved in
late 2015 (82) and results from phase III studies of andexanet
alfa, a recombinant modified FXa for the reversal of FXa
inhibitors, are positive (83). Also under development is PER977,
a synthetic small molecule that may eventually become a wide-
range reversal agent for anticoagulants. PER977 exhibits com-
plete reversal of FXa inhibition, direct thrombin inhibition, and
the anticoagulant effects of LMWH, unfractionated heparin, and
fondaparinux both in vitro and in preclinical animal models
and, more recently, for the reversal of edoxaban, a FXa inhibitor,
in healthy subjects (84).
Table 2 - Summary of key clinical trials of novel oral anticoagulants in the treatment of venous thromboembolism and pulmonary embolism.
Study Patient population Study treatment Key findings
Dabigatran
RE-COVER/
RE-COVER II
(64) (66)
Patients with acute symptomatic VTE Heparin or LMWH for 8-11 days, followed
by dabigatran 150 mg BID or warfarin
given in doses adjusted to an INR of 2.0-3.0
for 6 months
Dabigatran was noninferior to warfarin for
the prevention of recurrent or fatal VTE
and had a similar rate of major bleeding
but a lower risk of any bleeding events.
RE-MEDY
(65)
Patients completing at least 3 months
of VTE treatment who were considered
at increased risk of recurrent VTE
Dabigatran 150 mg or warfarin (adjusted
to an INR of 2.0-3.0)
Dabigatran was noninferior to warfarin
(adjusted to an INR of 2.0-3.0) for the
prevention of recurrent symptomatic and
objectively verified VTE or death
associated with VTE.
RE-SONATE
(65)
Patients completing at least 6 months of
treatment for VTE.
Dabigatran 150 mg BID or placebo Dabigatran significantly reduced the rate
of recurrent VTE but with a significantly
higher rate of major or CRNM bleeding
(5.3% vs. 1.8%).
Rivaroxaban
EINSTEIN-
DVT (67)
Patients with acute symptomatic DVT in
the deep veins of the knee or thigh,
but without any symptoms of PE
Rivaroxaban or standard therapy
(enoxaparin followed by VKA) for
3, 6, or 12 months
Rivaroxaban had non-inferior efficacy with
respect to the primary outcome, with
similar rates of major and CRNM bleeding.
EINSTEIN-PE
(68)
Patients with acute symptomatic PE with
or without symptomatic DVT
Rivaroxaban (15 mg BID for 3 weeks,
followed by 20 mg QD) or standard therapy
(enoxaparin followed by VKA) for 3, 6,
or 12 months
Rivaroxaban was non-inferior to
enoxaparin/VKA therapy for the
prevention of recurrent VTE, with similar
rates of total and CRNM bleeding.
However, rivaroxaban was associated with
a statistically significant reduction in major
bleeding events (HR, 0,49 [0,31-0,79]) in
patients with PE.
EINSTEIN-
EXT (67)
Patients who had previously completed 6 to
12 months of treatment with a VKA for an
acute episode of VTE or had participated in
the EINSTEIN-DVT or EINSTEIN-PE trials
Rivaroxaban 20 mg QD or placebo for
6 to 12 months
Rivaroxaban demonstrated superiority to
placebo for the primary outcome. Efficacy
and safety results were consistent across all
prespecified subgroups.
Apixaban
AMPLIFY
(69)
Patients presenting with acute DVT or PE Apixaban 10 mg BID for 7 days followed by
5 mg BID for 6 months or subcutaneous
enoxaparin for 5 days followed by dose-
adjusted warfarin for 6 months
There were no significant differences in the
rates of the primary efficacy outcome of
recurrent symptomatic VTE or VTE-related
death (2.3% vs. 2.7%, respectively)
between treatments, and apixaban was
associated with significantly fewer major
bleeding and CRNM bleeding events
compared with conventional therapy
(events occurred in 4.3% vs. 9.7% of
patients, respectively).
AMPLIFY-
EXT (70)
Patients with DVT/PE for whom there was
clinical uncertainty about whether to
continue oral anticoagulation after 6-12
months of routine treatment with a VKA
Placebo, apixaban 2.5 mg BID, or apixaban
5 mg BID for 12 months
Compared with placebo, both doses of
apixaban reduced the risk of recurrent
fatal or nonfatal VTE, while rates of major
bleeding were low and comparable to
those in the placebo group.
Edoxaban
HOKUSAI-
VTE (71)
Patients who presented with DVT or PE 5-7 days of heparin followed by
edoxaban 30 or 60 mg QD or warfarin
for 3-12 months
Edoxaban was noninferior to warfarin with
respect to the primary efficacy outcome of
recurrent symptomatic VTE, with less major
or CRNM bleeding compared with the
warfarin group.
BID: twice daily; CRNM: clinically relevant non-major; DVT: deep vein thrombosis; HR: hazard ratio; INR: international normalized ratio; LMWH: low-
molecular-weight heparin; PE: pulmonary embolism; QD: once daily; VKA: vitamin K antagonist; VTE: venous thromboembolism.
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Monitoring of anticoagulant effect
The use of DOACs has also been limited by the lack of a
readily available standardized assay for anticoagulant activity.
Despite the lack of a requirement for routine monitoring with
DOAC administration, situations may arise where monitoring
is desirable. The standard clotting assays used with heparin
derivatives and VKAs cannot be used to quantitatively assess
anticoagulant activity with DOACs, but other assays are
becoming available to facilitate point-of-care testing. A throm-
bin inhibitor assay suitable for use with dabigatran is now
commercially available, although its real value in the clinical
setting remains controversial (85). Tests based on chromogenic
FXa-specific inhibitor assays with appropriate calibrators are
now commercially available to assess the anticoagulant activity
of anti-FXa drugs such as rivaroxaban and apixaban, but their
clinical relevance has yet to be evaluated (86,87).
Adherence to treatment
Although the lack of a requirement to routinely monitor
anticoagulation with DOACs may be advantageous in some
situations, it may actually increase the likelihood of patients
stopping their anticoagulant treatment earlier than recom-
mended. Adherence may be particularly problematic where
health literacy is relatively low, such as in some Latin
American regions, and thorough education is needed to
ensure that patients adhere to their treatment regimens as
prescribed.
Increased drug costs
Drug purchase costs for DOACs are significantly greater than
those for generic warfarin. Cost is an important limitation to the
use of DOACs in Latin America, where many patients incur high
out-of-pocket health costs, with estimates for the average
percentage of household income spent on healthcare varying
by country from 2.0% to 6.9% (73). At present, the increased
drug cost may be partially offset by a reduction in the costs
associated with regular monitoring of the anticoagulant effect, as
well as potentially reduced costs relating to bleeding events and
hospitalizations. In addition, as DOACs become more widely
used, competition among the different agents may result in
lower prices over time. The higher drug costs associated with
DOACs compared with VKA therapy could be a factor in a
patient’s decision to discontinue anticoagulant therapy earlier
than would be advised by a healthcare provider.
Clinical experience
Finally, a lack of clinical experience in a specific patient
population compared with standard anticoagulant therapies
may also be a barrier to treatment. Clinical trial populations
may not accurately reflect the patient population in real-world
clinics, who are subject to multiple comorbidities (78),
polypharmacy (79) and other potential modifiers that would
have resulted in the exclusion of these patients from the original
trials. In addition to comorbidities and polypharmacy asso-
ciated with an increased risk of bleeding and worse clinical
outcomes (79 81), the presence of additional risk factors for
bleeding may make physicians more cautious about prescrib-
ing anticoagulants in general, particularly those with which
they have limited clinical experience. Over time, more data
regarding DOAC use in real-world patient populations will
become available, and as clinical experience with these agents
increases, this barrier to DOAC use is likely to be lowered.
VTE is a significant health problem in Latin America and
is complicated by various region-specific issues. In some
regions, awareness of diagnostic criteria for VTE is low. Many
patients do not receive appropriate anticoagulation even after
being diagnosed with VTE/PE. Clear guidance to facilitate the
diagnosis of VTE and provide appropriate anticoagulation for
patients once diagnosed may offer significant benefits in the
region. Heparin-based anticoagulants are likely to remain the
first choice for inpatients with VTE at high risk of bleeding or
with additional complications for which the doctor may desire
a precise level of control over anticoagulation. However,
DOACs may be particularly beneficial for outpatients requir-
ing anticoagulation, particularly in situations in which regular
monitoring may not be feasible.
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Table 3 - Anticoagulation therapy for patients with DVT or patients with PE in the absence of hypotension or shock.
Treatment Acute phase Maintenance phase
VKA + parenteral anticoagulation 7-10 days of treatment with
LMWH, UFH, or fondaparinux
(as appropriate)
VKA with a target INR of 2.0-3.0 to be initiated
in parallel to parenteral anticoagulation
Rivaroxaban can be considered as an alternative to the
combination of parenteral anticoagulation and VKA
in low-risk or ambulatory patients.
15 mg BID taken with food for
3 weeks
20 mg QD taken with food, initiated immediately
following acute phase treatment
Apixaban can be considered as an alternative to the
combination of parenteral anticoagulation and VKA in low-risk
or ambulatory patients.
10 mg BID for 7 days 5 mg BID, initiated immediately following
acute phase treatment
Dabigatran can be considered as an alternative to VKA
in ambulatory patients following 7-10 days of treatment
with a parenteral anticoagulant.
Not approved–use parenteral
anticoagulation
150 mg BID or 110 mg BID in patientsX80 years of
age, initiated immediately following acute phase
treatment
See prescribing information for individual agents for further information on contraindications or dosage adjustments in certain patient groups. All
recommendations below are subject to local regulatory approval of these agents for this indication.
BID: twice daily; DVT: deep vein thrombosis; INR: international normalized ratio; LMWH: low-molecular-weight heparin; PE: pulmonary embolism;
QD: once daily; UFH: unfractionated heparin; VKA: vitamin K antagonist.
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